No Data
Emerging markets stock digest: AVILEN surged significantly, with Immune Biosciences hitting the limit up.
Stalemate. On the 11th, after the close of trading, the performance for the fiscal year ending August 2024 was announced, and it has been in a stalemate even after starting to rise.
Hot stocks digest (morning session): JINSHD, KOZAIDOH HD, Bic Camera, etc.
Cosmos Pharmaceuticals <3349>: 7,729 yen (+409 yen) sharply rebounded. The company announced its first quarter earnings last weekend, with an operating profit of 11.6 billion yen, a 28.8% increase from the same period last year, exceeding the market consensus by about 2 billion yen. The gross profit margin of general food products has significantly improved. The unchanged full-year plan is 31.6 billion yen, a 0.3% increase from the previous year, and there is a conscious expectation of a significant upside. In addition, the same-store sales revenue for September announced at the same time decreased by 4.2% compared to the same month last year.
D&M Company --- decline, operating profit for the first quarter of the fiscal year ending in May 2025 increased by 18% compared to the same period last year, showing a solid performance.
Decreased. After the close of trading on the 11th, the performance for the first quarter of the fiscal year ending May 25th was announced. The revenue was 44.1 billion yen (+44.1% year-on-year), and the operating profit was 8.6 billion yen (+18.1% year-on-year), showing a solid performance. This was attributed to the steady increase in the number of credit purchase companies for F&I services, as well as the sales of large medical equipment in C&Br services. Additionally, in HR&OS services, preparations are underway to expand outsourcing services, with an expected increase in revenue from the second quarter onwards.
Ryohin Keikaku, operating profit up by 69.4% to 56.1 billion yen on August 24, financial estimates for August 25 showing a 2.0% decrease to 55 billion yen.
Ryohin Keikaku <7453> announced its financial results for the August 2024 period, with operating revenue increasing by 13.8% year-on-year to 661.677 million yen, and operating profit increasing by 69.4% to 56.135 million yen. Both operating revenue and each stage profit reached record highs. The improvement in operating gross profit margin was due to the effects of domestic price adjustments and the suppression of price reductions. For the August 2025 period, operating revenue increased by 10.9% year-on-year to 734 billion yen, while operating profit decreased by 2% to 55 billion yen.
Emerging markets outlook: Will the sluggishness in the growth market continue, and will short-term funds flow into recent ipos?
In the thin trading, it is difficult to grasp the direction of the index, and emerging markets fell this week. During the same period, while the Nikkei Average rose by +2.51%, the growth market index decreased by -1.50%, and the growth market 250 index decreased by -1.39%, highlighting the weakness of the growth market. Similar to the main board market, buying based on the rise of US stocks was seen at the beginning of the week, but with the trend of a strong yen and a high dollar, preference for large-cap stocks led to a heavy upper limit after the buying spree. The trading volume was 100 billion yen.
D&M Co: Presentation of financial results for the 1st quarter of the fiscal year ending May 2025
No Data
No Data